Recent Updates
Recently added Catalysts

AZD3355

Phase 2

Gastroesophageal Reflux Disease | Small molecule | Gastrointestinal |AstraZeneca PLC|Last Updated: Jun 14, 2011

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindCONTROLLEDBiomarker
Total Trials3
Total Enrollment105
FDA Designations
No designations recorded
Clinical Trials (3)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01043185A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May ExperiencePHASE2 COMPLETED 27Dec 1, 2009May 1, 2010Jun 14, 20111 United States
NCT00688402Study to Compare Different Formulations of AZD3355PHASE1 COMPLETED 48Apr 1, 2008Jun 1, 2008Dec 3, 20101 Sweden
NCT00684190Drug Interaction Study Between AZD3355 and NexiumPHASE1 COMPLETED 30Mar 1, 2008Jun 1, 2008Dec 3, 20101 Sweden
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Total Number of Reflux Episodes During 24 Hours
Measured during 24 hours at 4 different visits with a 7-28 days interval between

Number of reflux episodes assessed during ambulatory impedance-pH recording (defined as starting with a drop in impedance to below 50% of baseline and ending when impedance recovers to above 50% of baseline)

Specific AE questions
During 0-4 hours post dose
PK variables
Frequent sampling occasions during day 7 each treatment period
Secondary Endpoints
Number of Acid Reflux Episodes
Measured during 24 hours at 4 different visits with a 7-28 days interval between
Number of Weakly Acidic Reflux Episodes
Measured during 24 hours at 4 different visits with a 7-28 days interval between
Number of Weakly Alkaline Reflux Episodes
Measured during 24 hours at 4 different visits with a 7-28 days interval between
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingTRIPLE
ModelCROSSOVER
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
AEXPERIMENTALAZD3355 30 mg
BEXPERIMENTALAZD3355 90 mg
CEXPERIMENTALAZD3355 120 mg
DEXPERIMENTALAZD3355 240 mg
EPLACEBO_COMPARATORPlacebo
1EXPERIMENTALIR Formulation 65 mg
2EXPERIMENTALIR Formulation 150 mg
3EXPERIMENTALMR formulation, 1h 65 mg
4EXPERIMENTALMR Formulation, 1h 150 mg
5EXPERIMENTALMR Formulation, 2h 150 mg
Interventions
NameTypeDescription
AZD3355DRUG30 mg orally in the morning and 30 mg in the evening for 1 day
placeboDRUGPlacebo capsules orally in the morning and placebo capsules in the evening for 1 day
EsomeprazoleDRUG40 mg od, oral, 7 days
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 70 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Provide informed consent * History of GERD with persistent symptoms despite treatment with PPI * Otherwise normal physical health Exclusion Criteria: * History of GERD with symptoms that has not improved at all during treatment with PPI * Prior surgery of the upper gastroint...

Countries:United StatesSweden
Unlock Eligibility Criteria